BIOMARIN PHARMACEUTICAL INC — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
BioMarin completed acquisition of Amicus Therapeutics on April 27, 2026 for $5.07B (net of cash acquired). Q2 2026 revenues rose 20% YoY to $990M, driven by newly acquired GALAFOLD and POMBILITI+OPFOLDA products plus VOXZOGO growth. Company raised full-year 2026 total revenue guidance to $3.875–3.925B (from $3.825–3.925B) and Non-GAAP Diluted EPS to $4.90–5.10 (from $4.85–5.05). Amicus synergies of $280M GAAP ($220M Non-GAAP) targeted by 2028, representing ~50% of Amicus 2025 operating expenses. GAAP net income fell 81% QoQ to $45M due to integration costs, intangible amortization, and debt interest; Non-GAAP income declined 16% to $236M.
Why this rating
Transformational M&A—$5.1B deal ~76% of company market cap adds two major revenue streams, diversifies portfolio, and expands scale. Integration underway; accretion and synergies credible but execution risk remains. Near-term margin/EPS dilution offset by long-term growth and margin expansion expectations.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.